FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1321-1328 April 29, 1999 Number 17 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Inhibition of angiotensin-converting enzyme (ACE) reduces the risk of cardiovascular problems in patients with chronic renal failure. This effect may be due in part to a decrease in sympathetic nervous activity, but no direct evidence of such an action is available.

Methods We studied muscle sympathetic-nerve activity in 14 patients with hypertension, chronic renal failure, and increased plasma renin activity before, during, and after administration of the ACE inhibitor enalapril. Ten other patients with similar clinical characteristics were studied before and during treatment with the calcium-channel blocker amlodipine. Normal subjects matched for age and weight were included in both studies.

Results At base line, mean (±SD) muscle sympathetic-nerve activity was higher in the group of patients who received enalapril than in the control subjects (35±17 vs. 19±9 bursts per minute, P=0.004). The baroreflex curve, which reflects changes in muscle sympathetic-nerve activity caused by manipulations of blood pressure with sodium nitroprusside and phenylephrine, was shifted to the right in the patients, but baroreflex sensitivity was similar to that in the control subjects (–2.1±1.9 and –2.7±1.3 bursts per minute per mm Hg, respectively; P=0.36). A single dose of the sympatholytic drug clonidine caused a greater fall in blood pressure in the patients than in the control subjects. Treatment with enalapril normalized blood pressure and muscle sympathetic-nerve activity (at 23±10 bursts per minute) in the patients and shifted the baroreflex curve to the left, reflecting normal blood-pressure levels, without significantly changing sensitivity (–2.3±1.8 bursts per minute per mm Hg, P=0.96). In the patients who received amlodipine, treatment also lowered blood pressure but increased muscle sympathetic-nerve activity, from 41±19 to 56±14 bursts per minute (P=0.02).

Conclusions Increased sympathetic activity contributes to hypertension in patients with chronic renal disease. ACE inhibition controls hypertension and decreases sympathetic hyperactivity.

Source Information

From the Departments of Nephrology and Hypertension (G.L., P.J.B., I.H.H.K., L.-T.D.-O., H.A.K.) and Clinical Neurophysiology (P.L.O., G.H.W., A.C.H.), University Hospital Utrecht, Utrecht; and the Department of Internal Medicine, University Hospital Rotterdam, Rotterdam (F.B.) — both in the Netherlands.

Address reprint requests to Dr. Ligtenberg at the Department of Nephrology and Hypertension, University Hospital Utrecht, Rm. F03.226, P.O. Box 85.500, 3508 GA Utrecht, the Netherlands, or at gligtenb{at}digd.azu.nl.

Full Text of this Article

This article has been cited by other articles:

• Schlaich, M. P., Sobotka, P. A., Krum, H., Whitbourn, R., Walton, A., Esler, M. D. (2009). Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept. Hypertension 54: 1195-1201 [Full Text]  
• Schlaich, M. P., Socratous, F., Hennebry, S., Eikelis, N., Lambert, E. A., Straznicky, N., Esler, M. D., Lambert, G. W. (2009). Sympathetic Activation in Chronic Renal Failure. J. Am. Soc. Nephrol. 20: 933-939 [Abstract] [Full Text]  
• Kalaitzidis, R., Bakris, G. (2009). Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant 24: 701-702 [Full Text]  
• Park, J., Campese, V. M., Nobakht, N., Middlekauff, H. R. (2008). Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J. Appl. Physiol. 105: 1873-1876 [Abstract] [Full Text]  
• Craig, R. G., Hunter, J. M. (2008). Recent developments in the perioperative management of adult patients with chronic kidney disease. Br J Anaesth 101: 296-310 [Abstract] [Full Text]  
• Salem, R. M., Cadman, P. E., Chen, Y., Rao, F., Wen, G., Hamilton, B. A., Rana, B. K., Smith, D. W., Stridsberg, M., Ward, H. J., Mahata, M., Mahata, S. K., Bowden, D. W., Hicks, P. J., Freedman, B. I., Schork, N. J., O'Connor, D. T. (2008). Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease. J. Am. Soc. Nephrol. 19: 600-614 [Abstract] [Full Text]  
• Blankestijn, P. J. (2007). SYMPATHETIC HYPERACTIVITY--A HIDDEN ENEMY IN CHRONIC KIDNEY DISEASE PATIENTS. pdi 27: S293-S297 [Abstract] [Full Text]  
• Neumann, J., Ligtenberg, G., Klein, I. H.T., Boer, P., Oey, P. L., Koomans, H. A., Blankestijn, P. J. (2007). Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment. Hypertension 49: 506-510 [Abstract] [Full Text]  
• Lawson, C. R, Doulton, T. W, MacGregor, G. A (2006). Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease. Journal of Renin-Angiotensin-Aldosterone System 7: 139-145 [Abstract]  
• Julius, S., Weber, M. A., Kjeldsen, S. E., McInnes, G. T., Zanchetti, A., Brunner, H. R., Laragh, J., Schork, M. A., Hua, T. A., Amerena, J., Balazovjech, I., Cassel, G., Herczeg, B., Koylan, N., Magometschnigg, D., Majahalme, S., Martinez, F., Oigman, W., Seabra Gomes, R., Zhu, J.-r. (2006). The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy. Hypertension 48: 385-391 [Abstract] [Full Text]  
• Amann, K., Wanner, C., Ritz, E. (2006). Cross-Talk between the Kidney and the Cardiovascular System. J. Am. Soc. Nephrol. 17: 2112-2119 [Abstract] [Full Text]  
• Ravera, M., Re, M., Deferrari, L., Vettoretti, S., Deferrari, G. (2006). Importance of Blood Pressure Control in Chronic Kidney Disease. J. Am. Soc. Nephrol. 17: S98-S103 [Abstract] [Full Text]  
• Petersson, M., Friberg, P., Eisenhofer, G., Lambert, G., Rundqvist, B. (2005). Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 26: 906-913 [Abstract] [Full Text]  
• Bongartz, L. G., Cramer, M. J., Doevendans, P. A., Joles, J. A., Braam, B. (2005). The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11-17 [Abstract] [Full Text]  
• Neumann, J., Ligtenberg, G., Oey, L., Koomans, H. A., Blankestijn, P. J. (2004). Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal Failure. J. Am. Soc. Nephrol. 15: 2902-2907 [Abstract] [Full Text]  
• Velez-Roa, S., Ciarka, A., Najem, B., Vachiery, J.-L., Naeije, R., van de Borne, P. (2004). Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension. Circulation 110: 1308-1312 [Abstract] [Full Text]  
• Vonend, O., Apel, T., Amann, K., Sellin, L., Stegbauer, J., Ritz, E., Rump, L. C. (2004). Modulation of gene expression by moxonidine in rats with chronic renal failure. Nephrol Dial Transplant 19: 2217-2222 [Abstract] [Full Text]  
• Al-Hesayen, A., Parker, J. D. (2004). Impaired Baroreceptor Control of Renal Sympathetic Activity in Human Chronic Heart Failure. Circulation 109: 2862-2865 [Abstract] [Full Text]  
• Blankestijn, P. J. (2004). Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 19: 1354-1357 [Full Text]  
• Fournier, A., Messerli, F. H., Achard, J. M., Fernandez, L. (2004). Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43: 1343-1347 [Abstract] [Full Text]  
• Joles, J. A., Koomans, H. A. (2004). Causes and Consequences of Increased Sympathetic Activity in Renal Disease. Hypertension 43: 699-706 [Abstract] [Full Text]  
• Doulton, T. W., MacGregor, G. A (2004). Review: Blood pressure in haemodialysis patients: The importance of the relationship between the renin-angiotensin-aldosterone system, salt intake and extracellular volume. Journal of Renin-Angiotensin-Aldosterone System 5: 14-22 [Abstract]  
• Koomans, H. A., Blankestijn, P. J., Joles, J. A. (2004). Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call. J. Am. Soc. Nephrol. 15: 524-537 [Abstract] [Full Text]  
• van Orshoven, N. P., Oey, P. L., van Schelven, L. J., Roelofs, J. M. M., Jansen, P. A. F., Akkermans, L. M. A. (2004). Effect of gastric distension on cardiovascular parameters: gastrovascular reflex is attenuated in the elderly. J. Physiol. 555: 573-583 [Abstract] [Full Text]  
• Rabelink, T. J. (2004). Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?. Nephrol Dial Transplant 19: 23-26 [Full Text]  
• Klein, I. H.H.T., Ligtenberg, G., Neumann, J., Oey, P. L., Koomans, H. A., Blankestijn, P. J. (2003). Sympathetic Nerve Activity Is Inappropriately Increased in Chronic Renal Disease. J. Am. Soc. Nephrol. 14: 3239-3244 [Abstract] [Full Text]  
• Chan, C. T., Harvey, P. J., Picton, P., Pierratos, A., Miller, J. A., Floras, J. S. (2003). Short-Term Blood Pressure, Noradrenergic, and Vascular Effects of Nocturnal Home Hemodialysis. Hypertension 42: 925-931 [Abstract] [Full Text]  
• Julius, S. (2003). Bringing VALUE to LIFE. Eur Heart J Suppl 5: C5-C8 [Abstract]  
• Grassi, G., Seravalle, G., Turri, C., Bolla, G., Mancia, G. (2003). Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension. Hypertension 41: 558-562 [Abstract] [Full Text]  
• Klein, I. H.H.T., Ligtenberg, G., Oey, P. L., Koomans, H. A., Blankestijn, P. J. (2003). Enalapril and Losartan Reduce Sympathetic Hyperactivity in Patients with Chronic Renal Failure. J. Am. Soc. Nephrol. 14: 425-430 [Abstract] [Full Text]  
• Hausberg, M., Kosch, M., Harmelink, P., Barenbrock, M., Hohage, H., Kisters, K., Dietl, K. H., Rahn, K. H. (2002). Sympathetic Nerve Activity in End-Stage Renal Disease. Circulation 106: 1974-1979 [Abstract] [Full Text]  
• Zoccali, C., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Benedetto, F. A., Cataliotti, A., Malatino, L. S. (2002). Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. Hypertension 40: 41-46 [Abstract] [Full Text]  
• Binggeli, C., Corti, R., Sudano, I., Luscher, T. F., Noll, G. (2002). Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension. Hypertension 39: 892-896 [Abstract] [Full Text]  
• Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Stancanelli, B., Malatino, L. S. (2002). Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. Circulation 105: 1354-1359 [Abstract] [Full Text]  
• Hijmering, M. L., Stroes, E. S. G., Olijhoek, J., Hutten, B. A., Blankestijn, P. J., Rabelink, T. J. (2002). Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39: 683-688 [Abstract] [Full Text]  
• Leineweber, K., Heinroth-Hoffmann, I., Ponicke, K., Abraham, G., Osten, B., Brodde, O.-E. (2002). Cardiac {beta}-Adrenoceptor Desensitization Due to Increased {beta}-Adrenoceptor Kinase Activity in Chronic Uremia. J. Am. Soc. Nephrol. 13: 117-124 [Abstract] [Full Text]  
• Tycho Vuurmans, J. L., Boer, W. H., Bos, W.-J. W., Blankestijn, P. J., Koomans, H. A. (2002). Contribution of Volume Overload and Angiotensin II to the Increased Pulse Wave Velocity of Hemodialysis Patients. J. Am. Soc. Nephrol. 13: 177-183 [Abstract] [Full Text]  
• Curtis, B. M., O'Keefe, J. H. Jr (2002). Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight. Mayo Clin Proc. 77: 45-54 [Abstract]  
• KLEIN, I. H. H. T., LIGTENBERG, G., OEY, P. L., KOOMANS, H. A., BLANKESTIJN, P. J. (2001). Sympathetic Activity Is Increased in Polycystic Kidney Disease and Is Associated with Hypertension. J. Am. Soc. Nephrol. 12: 2427-2433 [Abstract] [Full Text]  
• De Wardener, H. E. (2001). The Hypothalamus and Hypertension. Physiol. Rev. 81: 1599-1658 [Abstract] [Full Text]  
• Vongpatanasin, W., Tuncel, M., Mansour, Y., Arbique, D., Victor, R. G. (2001). Transdermal Estrogen Replacement Therapy Decreases Sympathetic Activity in Postmenopausal Women. Circulation 103: 2903-2908 [Abstract] [Full Text]  
• Schomig, M., Eisenhardt, A., Ritz, E. (2001). Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 16: 469-474 [Full Text]  
• STROJEK, K., GRZESZCZAK, W., GÓRSKA, J., LESCHINGER, M. I., RITZ, E. (2001). Lowering of Microalbuminuria in Diabetic Patients by a Sympathicoplegic Agent: Novel Approach to Prevent Progression of Diabetic Nephropathy?. J. Am. Soc. Nephrol. 12: 602-605 [Abstract] [Full Text]  
• Rump, L. C., Amann, K., Orth, S., Ritz, E. (2000). Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia?. Nephrol Dial Transplant 15: 1735-1738 [Full Text]  
• Johansson, M., Elam, M., Rundqvist, B., Eisenhofer, G., Herlitz, H., Jensen, G., Friberg, P. (2000). Differentiated Response of the Sympathetic Nervous System to Angiotensin-Converting Enzyme Inhibition in Hypertension. Hypertension 36: 543-548 [Abstract] [Full Text]  
• Convertino, V. A., Ludwig, D. A. (2000). Validity of VO2 max in predicting blood volume: implications for the effect of fitness on aging. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279: R1068-R1075 [Abstract] [Full Text]  
• AMANN, K., RUMP, L. C., SIMONAVICIENE, A., OBERHAUSER, V., WESSELS, S., ORTH, S. R., GROSS, M.-L., KOCH, A., BIELENBERG, G. W., VAN KATS, J. P., EHMKE, H., MALL, G., RITZ, E. (2000). Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats. J. Am. Soc. Nephrol. 11: 1469-1478 [Abstract] [Full Text]  
• Blankestijn, P. J., Ligtenberg, G., Klein, I. H. H. T., Koomans, H. A. (2000). Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance. Nephrol Dial Transplant 15: 755-758 [Full Text]  
• Frohlich, E. D. (2000). Research Means "Look Back". Hypertension 35: 693-693 [Full Text]  
• Remuzzi, G. (1999). Sympathetic Overactivity in Hypertensive Patients with Chronic Renal Disease. NEJM 340: 1359-1361 [Full Text]